featured
Fulvestrant, Everolimus, and Anastrozole for the Front-Line Treatment of Advanced HR+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222
Clin. Cancer Res 2022 Jan 04;[EPub Ahead of Print], HCF Moore, WE Barlow, G Somlo, JR Gralow, AF Schott, DF Hayes, P Kuhn, JB Hicks, L Welter, PA Dy, CH Yeon, AK Conlin, E Balcueva, DL Lew, D Tripathy, L Pusztai, GN HortobagyiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.